Fig. 5: Enzalutamide facilitated the degradation activity of tautomycin in 22RV1 cells. | Cell Death Discovery

Fig. 5: Enzalutamide facilitated the degradation activity of tautomycin in 22RV1 cells.

From: Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

Fig. 5

A The protein levels of AR, AR-v7, PSA, and GAPDH were detected by Western blot in 22RV1 cells treated with indicated drugs and 1 nM DHT for 48 h. B The mRNA levels of KLK3 and TMPRSS2 were examined using qRT-PCR in 22RV1 cells with 1 nM DHT and indicated drug treatment for 48 h. C The half-life of AR and AR-v7 protein was explored in 22RV1 using Western blot in the presence of cycloheximide after 400 nM tautomycin or 10 μM enzalutamide treatment for 4, 8, and 12 h. D The ubiquitin level of AR was evaluated using co-immunoprecipitation in 22RV1 cells in the presence of 10 μM MG132 for 48 h. E The AR level was detected using Western blot in 22RV1 cells after treatment with gradient DHT and 400 nM tautomycin in the presence or absence of 1.5 μM enzalutamide. #Synergy by bliss-independent analysis.

Back to article page